1. Can Clinical Guidelines Afford to Ignore Cost Effectiveness? An Ethical Perspective

   • Kenneth Boyd
   • Peter Hall

   Editorial 20 February 2016 Pages: 529 - 531

2. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension

   • Shuyan Gu
   • Huimei Hu
   • Hengjin Dong

   Systematic Review 29 December 2015 Pages: 533 - 550

   

3. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals

   • Jagpreet Chhatwal
   • Tianhua He
   • Maria A. Lopez-Olivo

   Systematic Review 09 January 2016 Pages: 551 - 567

   

4. A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus

   • Martin Henriksson
   • Ramandeep Jindal
   • Michael Willis

   Systematic Review 20 January 2016 Pages: 569 - 585

   

5. Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence

   • Sebastian Hinde
   • Ros Wade
   • Eldon Spackman

   Review Article 28 January 2016 Pages: 587 - 596

6. Identification of Evidence for Key Parameters in Decision-Analytic Models of Cost Effectiveness: A Description of Sources and a Recommended Minimum Search Requirement

   • Suzy Paisley

   Practical Application 09 February 2016 Pages: 597 - 608

   

7. Biosimilars: How Can Payers Get Long-Term Savings?

   • Jorge Mestre-Ferrandiz
   • Adrian Towse
   • Mikel Berdud

   Current Opinion Open access 20 January 2016 Pages: 609 - 616

8. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health

   • Salah Ghabri
   • Françoise F. Hamers
   • Jean Michel Josselin

   Original Research Article 30 January 2016 Pages: 617 - 624